<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02557074</url>
  </required_header>
  <id_info>
    <org_study_id>14-API-01</org_study_id>
    <nct_id>NCT02557074</nct_id>
  </id_info>
  <brief_title>TREg Activation in the Treatment of the PELADE (Alopecia Areata)</brief_title>
  <acronym>TreatPelade</acronym>
  <official_title>TREg Activation in the Treatment of the PELADE (Alopecia Areata). Double Blind Randomized Placebo Controlled Comparative Study Using Low Doses of IL2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a prospective pilot study the investigators showed that low doses of IL2 could be
      beneficial for severe AA inducing a long lasting regrowth in 4 out of the 5 patients treated.

      The objective of this study is to compare the long term efficacy of low doses of IL2 versus
      placebo in a multicenter prospective randomized double blind study.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score Salt</measure>
    <time_frame>Once : at 12 months post-treatment</time_frame>
    <description>Success defined by a SALT score lower or equal to 25 at the end the study (12 months post-treatment). It will be calculated by 2 physicians blinded to the treatment received on standardized pictures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>at one day, 22 days, 43 days, 64 days, 251 days, 434 days</time_frame>
    <description>The quality of life (QdV) will be estimated with the scale DLQI which is a scale of QdV validated for the dermatological diseases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>at one day, 22 days, 43 days, 64 days, 251 days, 434 days</time_frame>
    <description>The tolerance will be clinically and biologically estimated at each visit. The type and the rank of every AE will be raised.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of patient</measure>
    <time_frame>at 12 months post-treatment</time_frame>
    <description>The satisfaction of the patients will be estimated on an analog visual scale(ladder) going of 0 (not satisfied) to 10 (very satisfied).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Alopecia Areata</condition>
  <arm_group>
    <arm_group_label>IL2 - Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will received IL2 low doses (1.5 to 3MUI/d) -
IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment
IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCl 9% serum (placebo) NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL2</intervention_name>
    <description>IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses</description>
    <arm_group_label>IL2 - Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment</description>
    <arm_group_label>Placebo - Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Of more than 18 years old,

          -  Affiliated to the social security system,

          -  Clinical diagnosis of alopecia areata,

          -  50 % of the surface of the scalp affected

          -  Last flaire started less than one year

          -  Alopecia areata resisting to at least 1 systematic treatment including phototherapy
             (UVB or PUVA), general corticosteroid therapy or methotrexate

          -  Signature of the informed consent

        Exclusion Criteria:

          -  Pregnancy or refusal of contraception at the women old enough to procreate,

          -  Refusal of contraception at the men

          -  Local treatment (dermocorticoïdes, minoxidil) or systematism (oral corticosteroid
             therapy, méthotrexate or the other immunosuppresseur) since less than 2 less,

          -  Evolutionary autoimmune cancer or disease or in forgiveness

          -  Excessive grip(taking) of alcohol (upper to 3 glasses of wine a day or one pre-lunch
             drink a day)

          -  Seropositivity VHC, VHB, or HIV

          -  Patient presenting a severe renal and/or hepatic insufficiency,

          -  Presenting patient one zoned, the chicken pox, the herpes, the tuberculosis, an
             evolutionary infectious disease, a respiratory failure …

          -  Vulnerable person (nobody under guardianship minor(miner), adults, deprived of
             freedom)

          -  IC in the treatment(processing) by IL-2R

          -  Presenting a contraindication to ProleukinR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Passeron Thierry, PUPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AP-HM - La timone - Dermatologie</name>
      <address>
        <city>Marseille</city>
        <state>Bouche Du Rhône</state>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AP-HP St Louis - Dermatologie</name>
      <address>
        <city>Paris</city>
        <state>Ile De France</state>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes - Dermatologie</name>
      <address>
        <city>Nîmes</city>
        <state>Languedoc-Roussillon</state>
        <zip>30000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI St Raphael Fréjus - Dermatologie</name>
      <address>
        <city>Fréjus</city>
        <state>Paca</state>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier - Dermatologie</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nice - dermatologie</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

